Clinigen Takes Aim At Unlicensed-To-Licensed Strategy With Quantum Buy

13 Sep 2017

• By John Davis

Extending its business in continental Europe, in niche generics and in the further development of unlicensed medicines are some of the drivers of Clinigen's latest proposed acquisition.

Target — Some patients need unlicensed medicines for their condition • Source: Shutterstock.

The UK pharmaceutical services company. Clinigen Group PLCis planning to acquire Quantum Pharma PLC in a cash-and-share deal valued at £150.3m ($199.5m), enlarging Clinigen's activities in the ethical supply of unlicensed medicines in the UK and continental Europe, and strengthening its role in commercializing medicine.

The interest of Clinigen in Quantum became public in the middle of last month, and the two AIM-listed companies have...